Modern complex treatment of microsporia

Author: S.I. Lavrushko1, 2

1 Ukrainian Medical Stomatological Academy, Poltava
2 ME «Poltava Regional Clinical Dermatovenerologic Dispensary оf Poltava Regional Council»


Objective — to increase the effectiveness of the treatment of children with microsporia by using Breveluck probiotic-vitamin complex in the complex therapy.

Materials and methods

55 sick children aged from 1 to 13 years (27 girls and 28 boys) were under observation: 28 had microsporia of the scalp, 10 had microsporia of the scalp and smooth skin, 17 — microsporia of smooth skin. 16 patients had associated colds: acute respiratory viral infections (14 cases) and their complications: laryngotracheitis (1 case), bronchitis (1 case). All patients with microsporia were divided into 3 groups. Patients of the 1st and 2nd groups were prescribed griseofulvin tablets (21—22 mg/kg). The daily dose was divided into 2—3 doses. All patients of the 3rd group were prescribed terbinafine depending on body weight: with body weight up to 20 kg — 62,5 mg/day (1/4 tablet), from 20 to 40 kg — 125 mg/day (1/2 tablet), 40 kg — 250 mg/day (1 tablet) once a day. Systemic therapy was combined with external treatment with 2 % sertaconazole nitrate cream. All patients with microsporia were prescribed Breveluck probiotic-vitamin complex depending on age: young children (from 1 to 3 years) — 1 capsule 1—2 times a day, children aged 3 to 12 years — 1 capsule 3 times a day, children over 12 years — 1—2 capsules 3 times a day. The duration of treatment in the 1st and 2nd groups ranged from 3 to 6 weeks, in the 3rd group — from 1 to 5 weeks. Patients after treatment were recommended to take the probiotic-vitamin complex Breveluck for 30 days.

Results and discussion

As a result of treatment, clinical and etiological recovery was achieved in all 55 patients. The duration of treatment in the 1st and 2nd groups ranged from 3 to 6 weeks, in the 3rd one — from 1 to 5 weeks. Introduction of probiotic-vitamin preparation Breveluck to the complex of treatment of patients with microsporia provided an opportunity to increase the effectiveness and improve the results of treatment, as also to avoid the development of concomitant colds. The drugs had good tolerability. No changes in blood and urine tests after the end of the course of therapy were noted.

Conclusions

The complex of probiotic cultures with vitamin components Breveluck is effective and safe in the case of microsporia of the scalp and smooth skin in children. Introduction of the probiotic-vitamin preparation Breveluck in combination with systemic antimycotics griseofulvin and terbinafine and antifungal 2 % sertaconazole nitrate cream into the complex of treatment of patients with microsporia helps to improve the effectiveness of treatment, accelerate clinical and mycological healing, as well as prevent recurrence of the disease and acute respiratory viral infections. This method turned out to be effective in treating patients for microsporia with associated colds and their complications.

Key words: microsporia, children, treatment, griseofulvin, terbinafine, sertaconazole nitrate, probiotic-vitamin complex.

Published in the journal “Ukrainian Journal of Dermatology, Venereology, Cosmetology” №2(73) ‘2019

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design